Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases

Mootaz M. Salman; Zaid Al-Obaidi; Philip Kitchen; Andrea Loreto; Roslyn M. Bill; Richard Wade-Martins

doi:10.3390/ijms22094688

Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases

Mootaz M. Salman^*, Zaid Al-Obaidi, Philip Kitchen, Andrea Loreto, Roslyn M. Bill, Richard Wade-Martins^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.

Original language	English
Article number	4688
Journal	International Journal of Molecular Sciences
Volume	22
Issue number	9
DOIs	https://doi.org/10.3390/ijms22094688
Publication status	Published - 28 Apr 2021

Bibliographical note

© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Keywords

Alzheimer’s disease
Amyotrophic lateral sclerosis
Brain diseases
CADD
CNS disorders
Dementia
Drug discovery
Huntington’s disease
Neurodegeneration
Parkinson’s disease

Access to Document

10.3390/ijms22094688Licence: CC BY 3.0

Advances in Applying Computer-Aided Drug Design
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Final published version, 928 KBLicence: CC BY 3.0

Cite this

@article{fa832b2351ac4cb684c78cae15450854,

title = "Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases",

abstract = "Neurodegenerative diseases (NDs) including Alzheimer{\textquoteright}s disease, Parkinson{\textquoteright}s disease, amyotrophic lateral sclerosis, and Huntington{\textquoteright}s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.",

keywords = "Alzheimer{\textquoteright}s disease, Amyotrophic lateral sclerosis, Brain diseases, CADD, CNS disorders, Dementia, Drug discovery, Huntington{\textquoteright}s disease, Neurodegeneration, Parkinson{\textquoteright}s disease",

author = "Salman, {Mootaz M.} and Zaid Al-Obaidi and Philip Kitchen and Andrea Loreto and Bill, {Roslyn M.} and Richard Wade-Martins",

note = "{\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",

year = "2021",

month = apr,

day = "28",

doi = "10.3390/ijms22094688",

language = "English",

volume = "22",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI AG",

number = "9",

}

TY - JOUR

T1 - Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases

AU - Salman, Mootaz M.

AU - Al-Obaidi, Zaid

AU - Kitchen, Philip

AU - Loreto, Andrea

AU - Bill, Roslyn M.

AU - Wade-Martins, Richard

N1 - © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PY - 2021/4/28

Y1 - 2021/4/28

N2 - Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.

AB - Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.

KW - Alzheimer’s disease

KW - Amyotrophic lateral sclerosis

KW - Brain diseases

KW - CADD

KW - CNS disorders

KW - Dementia

KW - Drug discovery

KW - Huntington’s disease

KW - Neurodegeneration

KW - Parkinson’s disease

UR - https://www.mdpi.com/1422-0067/22/9/4688

UR - http://www.scopus.com/inward/record.url?scp=85104869681&partnerID=8YFLogxK

U2 - 10.3390/ijms22094688

DO - 10.3390/ijms22094688

M3 - Review article

SN - 1661-6596

VL - 22

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 9

M1 - 4688

ER -

Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this